Robert H. Vonderheide, director of Penn’s Abramson Cancer Center, received a Stand Up to Cancer grant for his role as the leader of a Pancreatic Cancer Collective New Therapies Challenge Research Team. The team’s project is called “Antigenicity of mutant KRAS and impact on cancer evolution.” Their work will combine expertise in immunobiology and computational biology to analyze three unique, clinically curated datasets, including short- and long-term pancreatic cancer survivors, primary resected pancreatic cancers and mKRAS lung and colon cancers, to investigate how mKRAS immunogenicity may dictate outcomes. The two-year grant provides $225,000 for this research.